deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00002849

S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis

Phase II Study of Dexamethasone/Alpha-Interferon in AL Amyloidosis

Sponsor: Cancer and Leukemia Group B

Conditions Multiple Myeloma
Interventions dexamethasone recombinant interferon alfa
Updated 8 times since 2017 Last updated: Mar 5, 2015 Started: Nov 30, 1996 Primary completion: Dec 31, 1998 Completion: Jul 31, 2000
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00002849, this PHASE2 trial focuses on Multiple Myeloma and remains completed. Sponsored by Cancer and Leukemia Group B, it has been updated 8 times since 1996, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~May 2023 · 28 months · monthly snapshotCompleted~May 2023 – ~Jul 2024 · 14 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. May 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — May 2023 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Nov 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cancer and Leukemia Group B
  • National Cancer Institute (NCI)
  • SWOG Cancer Research Network
Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Boston, United States , Buffalo, United States , Burlington, United States , Chapel Hill, United States , Chicago, United States , Columbia, United States , Columbus, United States , Durham, United States , Iowa City, United States and 18 more locations